Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

NCT02940522 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women

Interventions

DRUG: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
DRUG: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

Sponsor

AMAG Pharmaceuticals, Inc.